A Phase 2/3 interventional study of 18F-DCFPyL PET/CT in Prostate Cancer, sponsored by Sir Mortimer B. Davis - Jewish General Hospital. Enrolling by invitation at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-27.
Sponsored by Sir Mortimer B. Davis - Jewish General Hospital · Phase 2/3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Prostatic Neoplasms by Sir Mortimer B. Davis - Jewish General Hospital — 4 open to participants now, 9 under way, 4 of them phase 3. Prostatic Neoplasms · Sir Mortimer B. Davis - Jewish General Hospital.
Among the 19 studies in Prostatic Neoplasms by Sir Mortimer B. Davis - Jewish General Hospital, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2018, is one of 2 in phase 2/3, and was the 13th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 19 studies in Prostatic Neoplasms by Sir Mortimer B. Davis - Jewish General Hospital are open now, in 1 country. Recruiting first, the newest first:
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+ · Men only
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+ · Men only
Sir Mortimer B. Davis - Jewish General Hospital · Sites in Canada
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 7
First in 2012; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 100 across the 15 interventional studies, 119 across the 4 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sir Mortimer B. Davis - Jewish General Hospital is the lead sponsor of 62 studies on the registry; 22 are open to participants now.
5 of the studies in Prostatic Neoplasms by Sir Mortimer B. Davis - Jewish General Hospital that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02685397Phase 3Sir Mortimer B. Davis - Jewish General HospitalManagement of Castration-Resistant Prostate Cancer with Oligometastases | 2027-04 |
| NCT03459820Phase 3Sir Mortimer B. Davis - Jewish General HospitalProstate Cancer Patient Management With 18F-DCFPyL PET/CT | 2027-06 |
| NCT02573636Sir Mortimer B. Davis - Jewish General HospitalThe Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy | 2026-11 |
| NCT06458855Sir Mortimer B. Davis - Jewish General HospitalNerve Grafting Technique to Restore Erectile Function Post Radical Prostatectomy | 2027-03 |
| NCT06521710Sir Mortimer B. Davis - Jewish General HospitalNerve Grafting Technique to Preserve Erectile Function in Patients Undergoing Robotic Assisted Radical Prostatectomy | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 19 studies in Prostatic Neoplasms by Sir Mortimer B. Davis - Jewish General Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, single-arm, open-label, phase III trial in patients with biopsy-proven prostate cancer. Patients will receive regular standard of clinical care. The only study-specific procedures will the administration of 18F-DCFPyL followed by a PET/CT scan. Differences in theoretical optimal clinical management based on a review of clinical, biochemical and radiographic subject data before and after 18F-DCFPyL PET/CT imaging by a central panel of experts will be captured at study completion.
Objectives: The primary objective of this study is to assess the differences in theoretical optimal clinical management afforded by 18F-DCFPyL PET/CT in prostate cancer patients as proposed by a central panel of experts.
Primary endpoint:
Secondary endpoints:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort A - High risk staging (HRS): Staging of high risk not previously treated patients as defined by any one of the following:
Cohort B - Biochemical recurrence: Restaging of biochemically recurrent prostate cancer patients as defined by increasing serum PSA on serial measurements and current PSA above 0.1 ng/ml following any treatment for prostate cancer.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
18F-DCFPyL PET/CT Scan
Diagnostic Test: 18F-DCFPyL PET/CT
18F-DCFPyL Positron Emission Tomography/Computed Tomography Scan
Differences in optimal clinical management
Differences in theoretical optimal clinical management based on a review of clinical, histopathological, biochemical and radiographic subject data both before and after 18F-DCFPyL PET/CT imaging retrospectively by a central panel of experts.
Time frame: 30 days
Scan positivity fraction in BCR by PSA.
18F-DCFPyL PET/CT scan positivity fraction in patients with biochemically recurrent prostate cancer, stratified by PSA.
Time frame: 30 days
Adverse events
Immediate AE up to 90 minutes post-administration of 18F-DCFPyL.
Time frame: 2 hours
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2018 (actual). Primary completion is estimated for Jun 2027, 108 months after the start.
Of 43 phase 2/3 interventional studies under Prostatic Neoplasms, half reached primary completion within 115 months of starting (the median), counting those still running; a quarter within 32. This study's planned 108 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sir Mortimer B. Davis - Jewish General Hospital